Actinic Keratosis Clinical Trial
Official title:
A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer
Verified date | June 2013 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This randomized phase II trial is studying how well T4N5 liposomal lotion works in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant. Chemoprevention therapy is the use of certain drugs to try to prevent the development of or recurrence of cancer. T4N5 liposomal lotion may be effective preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant.
Status | Completed |
Enrollment | 100 |
Est. completion date | |
Est. primary completion date | January 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - History of histologically confirmed nonmelanoma skin cancer - Renal transplant recipient = 4 years ago - Currently receiving standard multi-agent pharmacologic immunosuppression - Fitzpatrick skin type I, II, or III - Sun-damaged skin with = 10 lesions consistent with actinic keratoses OR wart on the upper extremities (arms, forearms, hands), neck, face, and exposed scalp combined - No history of keloid formation - No known photosensitivity disorder - No history of malignant melanoma - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No diagnosis of acute allograft rejection within the past 30 days requiring an increase in immunosuppression - No invasive malignancy within the past 4 years except curatively excised NMSC, cured polyclonal posttransplantation lymphoproliferative disease, carcinoma in situ of the cervix, stage 0 chronic lymphocytic leukemia, unless all of the following criteria are met: - No current evidence of disease - No treatment for the invasive malignancy within the past 6 months - No concurrent or planned therapy for the invasive malignancy - Has an expected disease-free survival of at least 5 years - No diagnosis of melanoma or melanoma in situ - No other medical or psychosocial condition that would preclude study participation - No likelihood, in the opinion of the transplant surgeon/nephrologist, to experience graft loss and/or discontinue standard immunosuppressive therapy during study treatment - More than 30 days since prior and no concurrent topical chemotherapy (including topical fluorouracil) to areas being studied - No concurrent topical preparations containing corticosteroids - More than 30 days since prior and no concurrent local radiotherapy to a study area - More than 30 days since prior and no concurrent cryotherapy to target lesions - No prior or concurrent experimental immunosuppressive agents - More than 30 days since prior investigational medication - More than 30 days since prior and no concurrent systemic psoralens or retinoids - More than 60 days since prior and no concurrent laser resurfacing, dermabrasion, or chemical peels to a study area - No other concurrent investigational agents - No other concurrent topical medications, including prescription and over the counter preparations, to the areas being studied (e.g., upper arms, forearms, neck, face, and scalp) - Concurrent moisturizer, emollient, and sunscreen allowed - No concurrent topical preparations containing vitamin A derivatives - No concurrent nonsteroidal anti-inflammatory drugs - Concurrent cardioprotective doses of aspirin (< 100 mg/day) allowed |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | UAB Comprehensive Cancer Center | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of nonmelanoma skin cancer (NMSC) | Descriptive statistics such as mean, median, standard deviation will be calculated to summarize the number of new NMSC for each of the two randomization arms and compared using the Wilcoxon rank-sum test. | Up to 18 months | No |
Secondary | Proportion of patients who develop NMSC during and after completion of study therapy | Calculated for the study drug and placebo arms and compared using the Fisher's exact or chi-square test. | Up to 18 months | No |
Secondary | Incidence of NMSC | Summarized by treatment arm and compared using the Wilcoxon rank-sum test. | Up to 18 months | No |
Secondary | Incidence of recurrent and de novo actinic keratoses (AKs) after completion of study therapy | Summarized by treatment arm and compared using the Wilcoxon rank-sum test. Similarly, multivariate Poisson regression model will be utilized to compare the cumulative number of incident AKs at the end of treatment as a function of treatment arm and covariates. | Up to 18 months | No |
Secondary | Number of regressed AKs after completion of study therapy | Summarized by treatment group and compared using the Wilcoxon rank-sum test. Similarly, multivariate Poisson regression model will be utilized to compare the cumulative number of regressed AKs at the end of treatment as a function of treatment group and covariates. In addition to the covariates listed above, the number of AKs at baseline will be included as a covariate in the model. | At 18 months | No |
Secondary | Risk of developing melanoma in both treated and untreated sites | The data will be collected and analyzed by scoring both total body melanoma distribution and those in lotion treatment sites. Relative risk will be calculated for the development of melanomas. The Chi-Square test will be used to explore the risk relationships. | Up to 18 months | No |
Secondary | Change in SEBs levels | Descriptive statistics will be calculated at baseline and end of treatment for several SEBs by treatment arm. The change in SEB levels will be also calculated for each patient and compared between treatment arms using either the two-sample t-test or Wilcoxon rank-sum test. | From baseline to 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03013647 -
Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization
|
N/A | |
Completed |
NCT02674048 -
Metvix Daylight PDT in Actinic Keratosis
|
||
Completed |
NCT02239679 -
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
|
Phase 2 | |
Completed |
NCT02421471 -
PMS to Evaluate the Safety and Efficacy of Picato® Gel
|
||
Completed |
NCT01686152 -
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
|
Phase 3 | |
Terminated |
NCT01525329 -
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
|
Phase 3 | |
Completed |
NCT01444989 -
Development and Validation of a Quality of Life Instrument for Actinic Keratosis
|
N/A | |
Completed |
NCT01449513 -
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
|
Phase 1 | |
Terminated |
NCT01203878 -
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
|
Phase 4 | |
Completed |
NCT00989313 -
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
|
Phase 3 | |
Completed |
NCT00306800 -
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
|
Phase 3 | |
Completed |
NCT00375739 -
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
|
Phase 2 | |
Completed |
NCT03285490 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
|
Phase 3 | |
Completed |
NCT03319251 -
Biomarker Database Registry for Photodynamic Therapy
|
||
Completed |
NCT02866695 -
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
|
Phase 4 | |
Completed |
NCT02952898 -
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
|
Phase 3 | |
Completed |
NCT02984072 -
Menthol for PDT Pain Relief
|
Phase 4 | |
Recruiting |
NCT03684772 -
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
|
Phase 2 | |
Completed |
NCT02878382 -
Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
|
N/A | |
Completed |
NCT02938715 -
Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil
|
N/A |